ArticleBiological psychiatry2016
Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.
Article in Biological psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05105542 (Muscarinic M1 Receptor Availability and Cognition in Schizophrenia), which is not on this map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Muscarinic M1 Receptor Availability and Cognition in Schizophrenia
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Association of CNR1 gene and cannabinoid 1 receptor protein in the human brain.Journal of neuroscience research · 2023Pooled it
- A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness.The American journal of drug and alcohol abuse · 2021Pooled it
- Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.Journal of psychopharmacology (Oxford, England) · 2018Pooled it
- Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis.Translational psychiatry · 2019Trial
- Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.JAMA psychiatry · 2018Trial
- Cannabinoid type 1 receptor availability imaging in attention-deficit/hyperactivity disorder using [EJNMMI reports · 2026Article
- Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.The American journal of psychiatry · 2026Review
- Distance-related functional connectivity alterations in first-episode, drug-naïve major depressive disorder: a resting-state fMRI study with atlas-based neurotransmitter correlates.BMC psychiatry · 2026Article
- Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Linking human brain functional connectivity to underlying neurotransmission.bioRxiv : the preprint server for biology · 2026Article
- The Brain Endocannabinoid System is Differentially Regulated in Male and Female Patients with First-Episode Psychosis.Schizophrenia bulletin · 2026Article
- PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders.Neuroscience bulletin · 2026Review
- Neural correlates of distance-related functional reorganization in obsessive compulsive disorder.Journal of psychiatry & neuroscience : JPN · 2026Article
- Mapping neurophysiological and molecular profiles of heterogeneity and homogeneity in schizophrenia-bipolar disorder.Science advances · 2025Article
- A Preliminary Investigation of Brain Cannabinoid Receptor Type 1 (CB1R) Availability in Men with Opioid Use Disorder.Research square · 2025Article
- The Role of Fatty Acid Amide Hydrolase, a Key Regulatory Endocannabinoid Enzyme, in Domain-Specific Cognitive Performance in Psychosis.Schizophrenia bulletin · 2025Article
- Two subtypes of major depressive disorder are identified from individualized gray matter morphological abnormalities in a large multi-site dataset.Psychological medicine · 2025Article
- Network spreading and local biological vulnerability in amyotrophic lateral sclerosis.Communications biology · 2025Article
- Mapping the microstructure of human cerebral cortex in vivo with diffusion MRI.Communications biology · 2025Article
- Benchmarking methods for mapping functional connectivity in the brain.Nature methods · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundSeveral lines of evidence suggest the presence of abnormalities in the endocannabinoid (eCB) system in schizophrenia (SCZ). However, there are limited in vivo measures of the eCB system in SCZ.
methodsTwenty five male SCZ subjects (SCZs) (18 antipsychotic treated and 7 antipsychotic free) were compared with 18 age-matched male healthy control subjects (HCs). Subjects underwent one positron emission tomography scan each with the cannabinoid receptor-1 (CB1R) selective radiotracer [(11)C]OMAR on the high resolution research tomography scanner. Regional volume of distribution (VT) values were determined using kinetic modeling of positron emission tomography data as a measure of CB1R availability. Group differences in mean composite [(11)C]OMAR VT values were compared between SCZs and HCs. Exploratory comparisons of CB1R availability within 15 brain regions were also conducted. All analyses were covaried for age and body mass index.
resultsSCZs showed significantly (p = .02) lower composite [(11)C]OMAR VT relative to HCs (~12% difference, effect size d = .73). [(11)C]OMAR VT was significantly (all ps < .05) lower in SCZs in the amygdala, caudate, posterior cingulate cortex, hippocampus, hypothalamus, and insula. Composite [11]OMAR VT was HCs > antipsychotic treated SZCs > antipsychotic free SZCs. Furthermore, composite [(11)C]OMAR VT was greater in HCs than SCZ smokers (n = 11) and SCZ nonsmokers (n = 14).
conclusionsCB1R availability is lower in male SCZ subjects compared with HCs. Furthermore, antipsychotics and tobacco use may increase CB1R availability in this population. The findings of the study provide further evidence supporting the hypothesis that alterations in the eCB system might contribute to the pathophysiology of SCZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.